Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst (Nasdaq: BCRX) reported Q1 2026 results: ORLADEYO net revenue $148.3M (+11% y/y; +21% comparable excl. Europe). The company recorded a GAAP operating loss $701.6M driven by a $697.8M acquired in‑process R&D charge from the Astria acquisition.
BioCryst closed a European license for navenibart with $70M upfront, up to $275M in milestones, and 18–30% tiered royalties. Cash and investments totaled $260.8M (pro forma $330.8M including $70M license proceeds). 2026 ORLADEYO revenue guidance remains $625M–$645M.
BioCryst (Nasdaq: BCRX) granted inducement restricted stock units to six newly hired employees covering an aggregate of 61,750 shares, effective May 1, 2026.
The RSUs were issued under Nasdaq Listing Rule 5635(c)(4), vest in four equal annual installments beginning on the one-year anniversary, and are subject to the Inducement Equity Incentive Plan and individual RSU agreements.
BioCryst (Nasdaq: BCRX) granted an Irish affiliate of Neopharmed Gentili an exclusive license to commercialize navenibart for hereditary angioedema in Europe. BioCryst will receive $70M upfront, up to $275M in regulatory and sales milestones, and tiered royalties of 18%–30%.
Navenibart is an investigational long‑acting plasma kallikrein inhibitor; BioCryst’s Phase 3 program is on track to support a U.S. regulatory filing by the end of 2027. The deal follows the 2025 sale of European ORLADEYO commercial rights to Neopharmed Gentili and aims to align regional commercialization and strengthen BioCryst’s near‑term finances.
BioCryst (NASDAQ:BCRX) will present at two investor conferences in May and June 2026. The company is scheduled to speak at the Bank of America Health Care Conference in Las Vegas on May 12, 2026 at 4:40 p.m. ET and at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 3:45 p.m. ET.
Live audio webcasts and replays will be available in the Investors & Media section of BioCryst’s website.
BioCryst (Nasdaq: BCRX) will report its first quarter 2026 financial results on Wednesday, May 6, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Investors can access the live call by phone or via a webcast with replay available on the company's investor website.
BioCryst (Nasdaq: BCRX) appointed Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer effective April 6, 2026. Menon joins from Alnylam, where he oversaw global clinical development and helped secure FDA approval of AMVUTTRA.
The company cited the Astria acquisition and the navenibart program moving toward a potential BLA as drivers for sharpening R&D strategy, balancing capital allocation, and preparing for additional rare‑disease launches.
BioCryst (Nasdaq: BCRX) granted inducement equity to 12 newly hired employees on April 1, 2026 under Nasdaq Listing Rule 5635(c)(4). The compensation committee awarded 33,950 stock options and 123,350 RSUs as of the grant date.
The options carry an exercise price of $9.38 (closing price on the grant date), a 10-year term, and both awards vest in four equal annual installments starting on the one-year anniversary, subject to continued service and plan terms.
BioCryst (Nasdaq:BCRX) announced inducement restricted stock unit grants to six newly hired employees covering an aggregate of 65,850 RSUs, granted as of March 2, 2026 under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date and are subject to the company’s Inducement Equity Incentive Plan and individual RSU agreements.
BioCryst (Nasdaq: BCRX) reported full year 2025 results and a business update on Feb 26, 2026. ORLADEYO net revenue was $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO). The company achieved record GAAP and non-GAAP operating profit, completed the Astria acquisition, and received FDA approval for ORLADEYO pellets for ages 2 to <12.
BioCryst maintained 2026 ORLADEYO revenue guidance of $625–$645 million and full year total revenue guidance of $635–$660 million.
BioCryst (Nasdaq: BCRX) will present at the T.D. Cowen 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026 at 9:10 a.m. ET.
According to the company, a live audio webcast and replay will be available in the Investors & Media section of BioCryst's website at www.biocryst.com.